Published in Ann Oncol on July 17, 2013
Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin Oncol (2015) 1.88
Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.79
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer. Breast Care (Basel) (2013) 0.90
Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis. PLoS One (2015) 0.80
Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options. Ther Adv Med Oncol (2015) 0.79
HER story: the next chapter in HER-2-directed therapy for advanced breast cancer. Oncologist (2013) 0.78
The expanding role of pertuzumab in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) (2015) 0.76
Health-related Quality of Life in Metastatic and Adjuvant Breast Cancer Patients. Geburtshilfe Frauenheilkd (2016) 0.75
Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations. Int J Womens Health (2014) 0.75
Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial. PLoS One (2015) 0.75
Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial. Qual Life Res (2016) 0.75
Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial. J Med Internet Res (2017) 0.75
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
The EGF receptor family as targets for cancer therapy. Oncogene (2000) 5.44
RENAL PLASMA FLOW AND SODIUM REABSORPTION AND EXCRETION IN CONGESTIVE HEART FAILURE. J Clin Invest (1948) 4.52
Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA (2001) 3.90
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res (2001) 3.62
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene (2011) 3.59
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol (2011) 3.55
"U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int (1998) 3.53
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol (1999) 3.48
Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J (2001) 3.21
Isolation of circovirus from lesions of pigs with postweaning multisystemic wasting syndrome. Can Vet J (1998) 3.19
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol (2010) 3.00
The role of tutoring in problem solving. J Child Psychol Psychiatry (1976) 2.97
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol (2004) 2.95
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol (2010) 2.94
Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med (1994) 2.84
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene (2008) 2.72
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol (2003) 2.63
Chronic Pulmonary Arteritis in Schistosomiasis Mansoni Associated with Right Ventricular Hypertrophy: Report of a Case. Am J Pathol (1935) 2.57
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol (2014) 2.50
Increased rate of suicide among patients with Huntington's disease. J Neurol Neurosurg Psychiatry (1984) 2.31
Ranitidine 150 mg twice daily vs 300 mg nightly in treatment of duodenal ulcers. Lancet (1984) 2.25
Obstructive sleep apnea in obese noninsulin-dependent diabetic patients: effect of continuous positive airway pressure treatment on insulin responsiveness. J Clin Endocrinol Metab (1994) 2.23
European Code Against Cancer and scientific justification: third version (2003). Ann Oncol (2003) 2.17
Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Curr Biol (1999) 2.17
Candida albicans endocarditis associated with a contaminated aortic valve allograft: implications for regulation of allograft processing. Clin Infect Dis (1998) 2.15
Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res (1993) 2.14
The experience of young people with depression: a qualitative study. J Psychiatr Ment Health Nurs (2011) 2.08
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. Ann Oncol (2013) 2.06
Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res (1993) 2.03
Reproduction of lesions of postweaning multisystemic wasting syndrome in gnotobiotic piglets. J Vet Diagn Invest (1999) 1.98
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol (2007) 1.96
Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience. Br J Cancer (1998) 1.96
Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol (2003) 1.96
Electrical activity during the 2006 Mount St. Augustine volcanic eruptions. Science (2007) 1.93
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol (2010) 1.91
Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol (1992) 1.89
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol (2004) 1.85
The relative incidence of anterior cruciate ligament injury in men and women at the United States Naval Academy. Am J Sports Med (2000) 1.83
The LS locus of pea encodes the gibberellin biosynthesis enzyme ent-kaurene synthase A. Plant J (1997) 1.82
Major new survey to identify and prioritise research issues for midwifery practice. Midwives Chron (1993) 1.80
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol (1998) 1.68
Selective arterial drug infusions in the treatment of acute gastrointestinal bleeding. A preliminary report. Gastroenterology (1970) 1.66
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol (2008) 1.66
Added value of molecular targeted agents in oncology. Ann Oncol (2011) 1.65
THE EFFECT OF SPINAL ANESTHESIA ON THE RENAL ISCHEMIA IN CONGESTIVE HEART FAILURE. J Clin Invest (1948) 1.64
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. Ann Oncol (2010) 1.63
A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer (2002) 1.62
Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res (1999) 1.59
Identification of a negative regulator of gibberellin action, HvSPY, in barley. Plant Cell (1998) 1.58
Chronic neurodegenerative disease associated with HTLV-II infection. Lancet (1992) 1.58
Muscle testing response to provocative vertebral challenge and spinal manipulation: a randomized controlled trial of construct validity. J Manipulative Physiol Ther (1994) 1.57
Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme. J Biol Chem (2001) 1.54
Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res (1987) 1.54
Effects of adrenaline and noradrenaline on coronary blood flow before and after beta-adrenergic blockade. Br J Pharmacol Chemother (1966) 1.54
Low-skill fibreoptic intubation: use of the Aintree Catheter with the classic LMA. Anaesthesia (2005) 1.53
Granulocyte-macrophage colony-stimulating factor in the innate immune response to Pneumocystis carinii pneumonia in mice. J Immunol (2000) 1.52
Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest (2002) 1.50
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene (2009) 1.48
Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative. Ann Oncol (2010) 1.48
Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol (2001) 1.46
Mammalian artificial chromosome formation from circular alphoid input DNA does not require telomere repeats. Hum Mol Genet (2000) 1.44
Sequential taxane and anthracycline-containing neoadjuvant regimens: the sequential order impact. Breast (2010) 1.43
Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin Invest (1997) 1.43
An electromagnetic catheter-flowmeter. Circ Res (1967) 1.42
High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br J Cancer (2008) 1.41
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol (2012) 1.40
Glacial-to-Holocene redistribution of carbonate ion in the deep sea. Science (2001) 1.40
Screening for gestational diabetes. Med J Aust (1992) 1.39
A role for a PDZ protein in the early secretory pathway for the targeting of proTGF-alpha to the cell surface. Mol Cell (1999) 1.39
Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer (1997) 1.39
Hydrophobic surfactant-associated protein in whole lung surfactant and its importance for biophysical activity in lung surfactant extracts used for replacement therapy. Pediatr Res (1986) 1.37
Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol (2009) 1.37
Trityl monitoring of automated DNA synthesizer operation by conductivity: a new method of real-time analysis. Biotechniques (1993) 1.36
Effects of a cardio-selective beta-adrenergic blocking agent on the heart and coronary circulation. Cardiovasc Res (1970) 1.35
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer (2009) 1.34
Physical growth and developmental outcome in very low birth weight premature infants at 3 years of age. J Pediatr (1985) 1.33
Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol (2001) 1.32
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer (2013) 1.31
Tamoxifen and contralateral breast cancer: the other side. J Natl Cancer Inst (2001) 1.30
Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology (Berl) (1999) 1.30
Circumcision and male-to-male sexual transmission of HIV. AIDS (2001) 1.30
Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer (2009) 1.30
A comparison of an effect of different anti-inflammatory drugs on human platelets. J Clin Pathol (1970) 1.27
A very short version of the Minnesota Aphasia Test. Br J Soc Clin Psychol (1980) 1.26
Porcine circovirus-2 and concurrent infections in the field. Vet Microbiol (2004) 1.24
BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer (2012) 1.24
Internode length in Pisum : A new, slender mutant with elevated levels of C19 gibberellins. Planta (1992) 1.24
Cosmetic and functional outcomes of breast conserving treatment for early stage breast cancer. 1. Comparison of patients' ratings, observers' ratings, and objective assessments. Radiother Oncol (1992) 1.24
Tamoxifen: the long and short of it. J Natl Cancer Inst (1996) 1.23
PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res (1997) 1.23
Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Ann Oncol (2007) 1.18
A simple method for measuring the relative force exerted by myosin on actin filaments in the in vitro motility assay: evidence that tropomyosin and troponin increase force in single thin filaments. Biochem J (2000) 1.17
Cardiac avoidance in breast radiotherapy: a comparison of simple shielding techniques with intensity-modulated radiotherapy. Radiother Oncol (2001) 1.17
Comparison of oxygen uptake during arm or leg cardiopulmonary exercise testing in vascular surgery patients and control subjects. Br J Anaesth (2013) 1.17
Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer (2008) 1.16